Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
26 hedge funds and large institutions have $420M invested in Sinovac Biotech, Ltd in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 26 → 26 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% less capital invested
Capital invested by funds: $421M → $420M (-$1.15M)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$1.04M |
| 2 |
JP Morgan Chase
New York
|
-$19.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.48K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.94K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $340M | – | – | – |
|
|
VC
2
Vivo Capital
Palo Alto,
California
| $76.3M | – | – | – |
|
|
NAH
3
Neumann Advisory (HK)
Central,
Hong Kong
| $2.04M | – | – | – |
|
4
Renaissance Technologies
New York
| $849K | – | – | – |
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $106K | – | – | – |
|
6
Geode Capital Management
Boston,
Massachusetts
| $89.7K | – | – | – |
|
|
7
Wells Fargo
San Francisco,
California
| $80.6K | -$1.94K | -300 | -2% |
|
|
8
Morgan Stanley
New York
| $50.6K | +$5.82K | +900 | +13% |
|
|
9
UBS Group
Zurich,
Switzerland
| $10.1K | -$3.48K | -538 | -26% |
|
10
Group One Trading
Chicago,
Illinois
| $2.67K | – | – | – |
|
|
TFA
11
Transamerica Financial Advisors
St. Petersburg,
Florida
| $1K | – | – | – |
|
|
HI
12
Horizon Investments
Charlotte,
North Carolina
| $336 | – | – | – |
|
|
13
State Street
Boston,
Massachusetts
| – | -$1.04M | -160,875 | Closed |
|
|
14
JP Morgan Chase
New York
| – | -$19.4K | -3,000 | Closed |
|
SVA Hedge Fund Activity: Q2 2024 in Review
26 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2024, worth a combined $420M — down 0.27% from $421M a quarter earlier.
Fund positioning in SVA was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 5 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $5.82K. The largest seller was State Street, exiting entirely with an estimated $1.04M sold.
- 26 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $420M of Sinovac Biotech, Ltd stock for Q2 2024, down 0.27% quarter-over-quarter.
- 2 funds opened new Sinovac Biotech, Ltd positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest Sinovac Biotech, Ltd buyer in Q2 2024 was Morgan Stanley, an estimated $5.82K added.
- The largest Sinovac Biotech, Ltd seller in Q2 2024 was State Street, an estimated $1.04M sold.
Based on aggregated 13F filings for Q2 2024.